Qilu, Pharmaceutical

Qilu Pharmaceutical announces the latest results from its clinical study on QL1706, in combination with chemotherapy, as a first-line treatment for recurrent or metastatic cervical cancer

Published on 08/07/2025 at 18:04 | prnewswire.co.uk

Qilu Pharmaceutical Co., Ltd. China Germany Switzerland United Kingdom France Netherlands Italy Spain Belgium United States of America Austria


Photo - https://mma.prnewswire.com/media/2257231/3.jpg 
Logo - https://mma.prnewswire.com/media/2073821/4362099/QILU_logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/qilu-pharmaceutical-announces-the-latest-results-from-its-clinical-study-on-ql1706-in-combination-with-chemotherapy-as-a-first-line-treatment-for-recurrent-or-metastatic-cervical-cancer-301967435.html

en | boerse | 67988853 |